Inventiva(IVA) Stock Price Today | Quotes & News

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Inventiva SA Earnings Call: Positive Outlook Amid Challenges
TipRanksMar 28 20:01 ET
H.C. Wainwright Maintains Inventiva(IVA.US) With Buy Rating, Maintains Target Price $13
Moomoo NewsMar 28 17:31 ET · Ratings
Inventiva Price Target Maintained With a $13.00/Share by HC Wainwright & Co.
Dow JonesMar 28 08:50 ET · Ratings
Inventiva's Strategic Positioning and Clinical Progress Drive Buy Rating Amid Promising MASH Therapy Developments
TipRanksMar 28 08:45 ET · Ratings
Inventiva Analyst Ratings
BenzingaMar 28 08:38 ET · Ratings
Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript Summary
moomoo AIMar 27 10:59 ET · Conference Call

Comments

Jaguar8

Feb 27 05:00

NEWS

$Inventiva (IVA.US)$
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment
Wednesday, 26th February at 4:00 pm
• The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and prehepatic non-fibrotic PH
• Lanifibranor was observed to decrease portal pressure by improving Liver Sinusoidal Endothelial Cell (LSEC) dysfun...

1

Jaguar8

Feb 21 05:00

NEWS

$Inventiva (IVA.US)$
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
Thursday, 20th February at 4:00 pm
• Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 study
• Positive results could support the initiation of a pivotal Phase 3 trial in patients in Japan with MASH
• The study represents...

1

Jaguar8

Jan 30 05:00

NEWS

$Inventiva (IVA.US)$
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology
Wednesday, 29th January at 4:00 pm
• As previously reported1, the study met the primary efficacy endpoint for the treatment with lanifibranor 800mg demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of t...

Jaguar8

Jan 23 13:28

🟤 Watchlist, JANUARY 23,2025, Thursday. NFA

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards t...

61

17

9

Jaguar8

Jan 23 05:00

NEWS

$Inventiva (IVA.US)$
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
Wednesday, 22nd January at 4:00 pm
Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfu...

IVA Inventiva

Trade Overview

Capital Trend

News

Comments

Market Insights